Group 1 - The top three AH premium rates are held by Northeast Electric (00042) at 831.03%, Zhejiang Shibao (01057) at 349.11%, and Sinopec Oilfield Service (01033) at 287.64% [1] - The bottom three AH premium rates are recorded by CATL (03750) at -13.68%, China Merchants Bank (03968) at -2.20%, and WuXi AppTec (02359) at 2.64% [1] - The highest deviation values are seen in Andeli Juice (02218) at 23.04%, Dongpeng Beverage (09980) at 20.81%, and Goldwind Technology (02208) at 14.41% [1] Group 2 - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) at 270.81% and Beijing Mechanical and Electrical (00187) at 255.83% [1] - The bottom ten AH stocks by premium rate include companies like Hengrui Medicine (01276) at 2.75% and Weichai Power (02338) at 7.14% [1] - The top ten AH stocks by deviation value also feature Qingdao Bank (03866) at 13.73% and CanSino Biologics (06185) at 13.21% [1]

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. - Junshi Biosciences has a complete industry chain capability from drug discovery and development to large-scale production and commercialization, aiming to become a globally positioned innovative pharmaceutical company [3]. Group 2: Product Pipeline and Innovations - The core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and an additional supplemental NDA under review, showcasing the company's strong market presence [3]. - The company’s self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III registration clinical studies and multiple Phase Ib/II studies in progress [3]. - Junshi Biosciences is exploring early-stage pipelines, with several products expected to initiate critical registration clinical trials by 2025 [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 4: Market Position and Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [9]. - The company is part of the pharmaceutical and biotechnology sector, focusing on biopharmaceuticals, including COVID-19 drugs, monkeypox concepts, viral prevention, and precision medicine [9].

上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿 元，较原计划多17.97亿元。君实生物于2020年7月8日发布的招股说明书显示，该公司计划募集资金 27.00亿元，分别用于创新药研发项目、君实生物科技产业化临港项目、偿还银行贷款及补充流动资 金。 君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。 君实生物2022年度向特定对象发行A股股票募集资金情况为，根据中国证监会出具的《关于同意上 海君实生物医药科技股份有限公司向特定对象发行股票注册的批复》（证监许可[2022]2616号），公司 获准向特定对象发行人民币普通股7,000.00万股，每股发行价格为人民币53.95元，募集资金总额为人民 币3,776,500,000.00元；扣除各项发行费用合计人民币31,697,205.06元（不含增值税）后，实际募集资金 净额为人民币3,744,802,794.94元。实际到账金额为人民币3,759,350,000.00元，包括尚未支付的其他发行 费用人民币14,547 ...

Group 1 - As of January 31, 2026, over 3,006 listed companies in A-shares disclosed their performance forecasts for 2025, representing 55.1% of all A-shares, slightly higher than 53.4% in 2024 [10][12] - The forecasted positive performance rate for 2025 is 36.7%, an increase of 3.3 percentage points from 2024, while the negative performance rate decreased from 66.2% in 2024 to 63.3% [14][15] - The proportion of companies expecting profit increases has risen significantly, with the share of profit-increasing companies reaching 21.1%, indicating a potential recovery in profit growth [15][18] Group 2 - The performance forecast rates for major indices such as CSI 300, ChiNext, and CSI 500 are around 60%, primarily driven by profit increases, indicating a recovery trend among large and mid-cap companies [18][19] - In contrast, the CSI 1000 index has a positive performance rate of only 37%, with a high proportion of companies still facing losses, reflecting weaker overall profitability [18][19] - The non-bank financial sector shows a high positive performance rate of 88%, with 72% of companies expecting profit increases, while the real estate sector has a low positive performance rate of only 18% [22][24] Group 3 - The analysis of performance changes indicates that AI, overseas exports, anti-involution, and price increases are the core growth drivers for over 40% of high-performing companies [22][24] - The performance of companies benefiting from AI is expanding beyond the tech sector into midstream manufacturing, while more industries are starting to gain from overseas exports [22][24] - The performance of companies in the anti-involution sector is expected to be a key area of focus for 2025, as they show a higher proportion of exceeding performance forecasts [22][24] Group 4 - The distribution of performance growth rates shows a rightward shift in the "U" shape curve, indicating an increase in companies experiencing recovery from difficulties [24][29] - The overall net profit growth rate for A-shares is projected to reach 29.6% year-on-year, with a median growth rate of 12.4%, suggesting a solidifying trend in profitability [29][32] - The fourth quarter of 2025 is expected to maintain high resilience in net profit growth, contrasting with the declines seen in previous years [29][32]

截至9月30日，君实生物股东户数3.59万，较上期增加15.17%；人均流通股21361股，较上期减少 12.96%。2025年1月-9月，君实生物实现营业收入18.06亿元，同比增长42.06%；归母净利润-5.96亿元， 同比增长35.72%。 机构持仓方面，截止2025年9月30日，君实生物十大流通股东中，易方达上证科创板50ETF（588080） 位居第七大流通股东，持股1939.29万股，相比上期减少282.03万股。华夏上证科创板50成份ETF （588000）位居第八大流通股东，持股1897.20万股，相比上期减少1074.47万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融资方面，君实生物当日融资买入5342.70万元。当前融资余额14.64亿元，占流通市值的5.32%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，君实生物1月30日融券偿还2350.00股，融券卖出300.00股，按当日收盘价计 ...

Market Performance - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 2.23% to 26,775.57 points, and the Hang Seng Tech Index dropping by 3.36% to 5,526.31 points [1] - Major technology stocks saw significant losses, including Alibaba down 3.49%, Tencent down 1.24%, and JD.com down 1.69% [1] - Gold and silver prices fell sharply, with Shandong Gold and Chifeng Gold both dropping over 12% [1] Company Earnings Forecasts - Haiprime (09989.HK) expects a net profit of 284 million to 377 million yuan for 2025, a decrease of 41.71% to 56.09% year-on-year [2] - Datang Power (00991.HK) anticipates a net profit of approximately 6.8 billion to 7.8 billion yuan for 2025, an increase of about 51% to 73% year-on-year [6] - Longhua Automobile (02333.HK) projects total revenue of 222.79 billion yuan for 2025, a year-on-year growth of 10.19% [4] - CICC (03908.HK) forecasts a net profit of 8.542 billion to 10.535 billion yuan for 2025, an increase of 50% to 85% year-on-year [5] Company Warnings - Kaisa New Energy (01108.HK) issued a profit warning, expecting a net loss increase of approximately 90.07 million to 290 million yuan for 2025 [7] - Xinyi Alloy (00505.HK) also issued a profit warning, anticipating a 50% decrease in profit attributable to equity shareholders for 2025 [8] - Fudan Zhangjiang (01349.HK) expects a net loss of approximately 120 million to 180 million yuan for 2025 [9] Strategic Developments - Innovation Intelligence (02121.HK) signed a strategic cooperation agreement with Shanghai Jiao Tong University Hainan Research Institute [11] - Zhonghui Biotech-B (02627.HK) received approval from the National Medical Products Administration for its trivalent influenza virus subunit vaccine [12]

Core Viewpoint - Junshi Biosciences expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year growth of about 28.32% [1] Revenue and Profit Forecast - The projected R&D expenses are estimated at 1.353 billion yuan, an increase of approximately 6.10% compared to the previous year [1] - The expected net profit attributable to shareholders is a loss of approximately 873 million yuan, which is a reduction in losses compared to the previous year [1] - After excluding the impact of share-based payments, the expected net profit attributable to shareholders is a loss of about 799 million yuan, reflecting a year-on-year decrease in losses of approximately 37.62% [1] - The expected net profit attributable to shareholders, after excluding non-recurring gains and losses, is a loss of about 985 million yuan, which is a reduction in losses of approximately 23.64% [1] Revenue Growth Drivers - The growth in revenue is primarily attributed to the significant increase in sales of the core product, Toripalimab injection (Tuoyi®), in the domestic market [1] - Tuoyi® has been approved for 12 indications, all of which are included in the national medical insurance catalog, and has been approved for sale in multiple countries and regions globally [1] Cost Management and Future Plans - Despite the continued net loss, the company has significantly narrowed the loss amount, mainly due to ongoing efforts in quality improvement and cost control [1] - The company plans to accelerate the clinical trials of several innovative drugs that have competitive advantages in international markets [1]

盘面上，大型科技股普跌，阿里巴巴跌3.25%，腾讯控股跌1.32%，京东集团跌1.6%，小米集团跌 2.99%，网易跌3.41%，美团跌2.67%，快手跌3.49%，哔哩哔哩跌4.47%；黄金股继续下跌，山东黄金跌 超10%；汽车股走弱，小鹏汽车跌9%；芯片股跌幅居前，华虹半导体（核心股）跌超10%；澳门1月博 彩收入胜预期，濠赌股逆势上涨。 企业资讯 海普瑞(09989.HK)：预计2025年净利润2.84亿元-3.77亿元，同比下降41.71%-56.09%。 大唐发电(00991.HK)：2025年累计完成上网电量约2731.092亿千瓦时，同比上升约1.41%。 长城汽车(02333.HK)：2025年营业总收入2227.9亿元，同比增长10.19%；净利润99.12亿元，同比减少 21.71%。 中金公司(03908.HK)：预计2025年净利润85.42亿元到105.35亿元，同比增加50%到85%。 2月2日，港股早盘低开低走全线下挫，截止午盘，恒生指数跌2.4%报26730.78点，恒生科技指数跌 3.68%报5507.77点，国企指数跌2.71%报9064.43点，红筹指数跌2.75%报42 ...

1月31日，君实生物发布业绩预告，预计去年全年实现营业收入约25亿元，同比增长约28.32%；预计归母净利润亏损约8.73亿元，同比减亏31.85%；作为 创新药公司，公司自2020年7月上市以来至今已5年半，仍未扭转亏损态势，5年累计亏损约92亿元。 对于业绩变化，君实生物解释称，报告期内，主要系商业化药品的销售收入与上年同期相比有所增长。报告期内，公司核心产品特瑞普利单抗注射液(商 品名：拓益)于国内市场销售收入同比大幅增长。截至公告披露日，拓益已在中国内地获批上市的12项适应症全部纳入国家医保目录，是目录中唯一用于 肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物。 公司表示，去年归母净利润仍出现亏损，但亏损金额相比显著缩窄，主要系公司商业化能力显著提升的同时不断加强费用管控与资源聚焦。 截至目前，特瑞普利单抗已在中国内地、中国香港、美国、欧盟、印度、英国、约旦、澳大利亚、新加坡、阿联酋、科威特、巴基斯坦、加拿大和巴林等 40多个国家和地区获批上市，并在全球多个国家和地区接受上市审评。 值得一提的是，最近几个月君实生物率遭股东减持。去年12月18日晚间，君实生物称，上海檀英计划通过大宗交易的方式减持 ...

3、港股通5日占比增持榜（前10名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 钧达股份(02865) | +12.94% | 62.00% | | 南华期货股份(02691) | +9.45% | 11.03% | | 山东墨龙(00568) | +3.83% | 61.06% | | 君实生物(01877) | +3.41% | 56.39% | | 百奥赛图-B(02315) | +3.25% | 23.55% | | 中伟新材(02579) | +2.87% | 16.58% | | 长飞光纤光缆(06869) | +2.50% | 57.18% | | 南方东西精选(03441) | +2.33% | 16.05% | | 新意网集团(01686) | +2.26% | 7.24% | | 方舟健客(06086) | +1.96% | 6.24% | 智通财经APP获悉，根据2026年1月30日披露数据，山东墨龙（00568）、钧达股份（02865）、京城机 电股份（00187）港股通持股占比增加值最大，分别增加2.80%、2.32%、1.51% ...